Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 17/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343158 | 0.84 | KDM4E (0.52) | MAPK8MAPK9MEN1LMNAKMT2A | |
| SCHEMBL29954953 | 0.84 | KDM4E (0.52) | MAPK8MAPK9MEN1LMNAKMT2A | |
| SCHEMBL1144648 | 0.82 | KDM4E (0.44) | MAT2AMAPK8CYP1A2 | |
| SCHEMBL1144030 | 0.82 | MAT2A (0.40) | MAT2AMAPK8MAPK9PRMT5LMNA | |
| SCHEMBL2345291 | 0.82 | NPSR1 (0.44) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL2345150 | 0.81 | NPSR1 (0.49) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL2349748 | 0.77 | KMT2A (0.39) | MAT2AMEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL1149900 | 0.77 | REN (0.40) | MEN1KMT2A | |
| SCHEMBL29955023 | 0.76 | KMT2A (0.49) | MEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL2341924 | 0.76 | ALDH1A1 (0.48) | MAPK8MAPK9MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2247575-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095163-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | MAT2A 1339/4885MAPK8 2253/4885MAPK9 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.